Heptares enters a research and drug discovery collaboration with Juntendo University
Advertisement
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan.
The new collaboration, Heptares’ fourth ORBIT programme, is with the research group of Professor Takehiko Yokomizo, an expert on Molecular Biology, Immunology and Cell Biology and Professor of Department of Molecular and Cellular Biochemistry at Juntendo University. The collaboration is the first international industrial partnership for this prestigious university. Research activities will focus on the bespoke design and profiling of novel leukotriene receptor modulators with potential therapeutic utility in intractable skin/intestinal ulcers.
Fiona Marshall, Chief Scientific Officer of Heptares, said: “We are delighted to collaborate with Professor Yokomizo and his group at Juntendo University. Their extensive experience and knowledge of leukotriene receptors, combined with our own structure-based design expertise, forms a strong basis from which to generate novel selective, small molecules with the potential to address difficult-to-treat wounds. We look forward to a productive relationship.”
Prof. Yokomizo, Juntendo University, added: “Heptares has a strong global reputation based on its GPCR drug design capabilities. We are excited to collaborate on this new project, which has the potential to significantly advance our knowledge of the links between leukotriene receptor and disease, and to progress new drug design strategies in this area.”
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Novasep and instrAction enter a worldwide strategic alliance for non-chiral chromatography
Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH
Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system
Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin - Cambridge Researcher to Further Studies of Obesity, Fatty Liver Disease
